Background: In Graves’s disease, there is a lack of description specific to the gender and age among sub-Saharan African subject. The objective was to evaluate the impact of gender and age on the profile of Graves’ disease in Senegalese subject in order to understand the evolution and improve the therapeutic choices. Methods: This is a retrospective study conducted from January 1, 2010 to December 31, 2017 (07 years) at Abass Ndao University Hospital (Senegal), focused on patients with Graves’ disease followed up under antithyroid drugs treatment for at least 18 months. Results: There were 244 men, 404 subjects between [0 - 25 years], and 101 subjects more than 50 years old. Factors associated with goitre size were male gender (p < 0.001), young age (p < 0.001). Graves orbitopathy was correlated with male gender (p = 0.015), and young age (p < 0.001). Among 580 patients who had stopped medical treatment after more than 18 months of follow-up, relapse involved in 30.3%. Durable remission was achieved in 38.8% of all included patients and 69.7% of subjects who had a cessation of medical treatment. The factors associated with sustained remission were female gender (p = 0.049), absence of orbitopathy (p = 0.011), small goiter (p < 0.001), advanced age (p = 0.006) and early start of the maintenance treatment (p = 0.006). Conclusion: In our Senegalese study, men and young patients are particularized by a trend of voluminous goitre and low rate of remission. These data remain a basis for predicting the outcome of medical treatment and make timely use of radical treatments such as surgery or irratherapy in the presence of risk factors for recurrence.
References
[1]
Wémeau, J.L., et al. (2006) Hyperthyroidism: Encycl Méd. Chir. Endocrinologie-Nutrition. Paris, France, 17.
[2]
Diop, S.N., Diédhiou, D., Sarr, A., et al. (2011) Psychological Aspects and Psychiatric Manifestation of Grave’s Disease about 104 Cases. Revue du CAMES, 12, 62-64.
[3]
Sarr, A., Diédhiou, D., Ndour-Mbaye, N.M., et al. (2016) Graves’ Disease in Senegal: Clinical and Evolutionary Aspects. Open Journal of Internal Medicine, 6, 77-82. https://doi.org/10.4236/ojim.2016.63013
[4]
Ka-Cissé, M., Diop, S.N., Ndour, M., Sarr, A., Sidibé, E.H. and Sow, A.M. (1999) Graves’ Disease in Children and Adolescents in Senegal. La Revue francaise d’endocrinologie clinique, nutrition, et metabolisme, 40, 99-106.
[5]
Diédhiou, D., Diallo, I.M., Ndour, M.A., et al. (2018) Graves’ Disease in Men’s Subjects. Journal of Human Endocrinology, 3, 12. https://doi.org/10.24966/HE-9640/100012
[6]
Abraham-Nordling, M., Bystrom, K., Torring, O., et al. (2011) Incidence of Hyperthyroidism in Sweden. European Journal of Endocrinology, 165, 899-905. https://doi.org/10.1089/thy.2016.0229
[7]
Ross, D.S., Burch, H.B., Cooper, D.S., et al. (2016) American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid, 26, 1343-1421. https://doi.org/10.1089/thy.2016.0229
[8]
Wartofsky, L., Glinoer, D., Solomon, B., et al. (1991) Differences and Similarities in the Diagnosis and Treatment of Graves’ Disease in Europe, Japan, and the United States. Thyroid, 1, 129-135. https://doi.org/10.1089/thy.1991.1.129
[9]
Kimball, L.E., Kulinskaya, E., Brown, B., Johnston, C. and Farid, N.R. (2002) Does Smoking Increase Relapse Rates in Graves’ Disease? Journal of Endocrinological Investigation, 25, 152-157. https://doi.org/10.1007/BF03343979
[10]
Allahabadia, A., Daykin, J., Holder, R.L., Sheppard, M.C., Gough, S.C.L. and Franklyn, J.A. (2000) Age and Gender Predict the Outcome of Treatment for Graves’ Hyperthyroidism. The Journal of Clinical Endocrinology & Metabolism, 85, 1038-1042. https://doi.org/10.1210/jc.85.3.1038
[11]
Perez, C., Scrimshaw, N.S. and Munoz, J.A. (1960) Technique of Endemic Goitre Surveys. Monograph Series. World Health Organization, 44, 369-383.
[12]
Bartalena, L., Baldeschi, L., Dickinson, A.J., et al. (2008) Consensus Statement of the European Group on Graves’ Orbitopathy (EUGOGO) on Management of GO. European Journal of Endocrinology, 158, 273-285. https://doi.org/10.1530/EJE-07-0666
[13]
Goichot, B., Caron, P., Landron, F. and Bou, S. (2016) Clinical Presentation of Hyperthyroidism in a Large Representative Sample of Outpatients in France: Relationships with Age, Etiology and Hormonal Parameters. Clinical Endocrinology, 84, 445-451. https://doi.org/10.1111/cen.12816
[14]
Diagne, N., Faye, A., Ndao, A.C., et al. (2016) Epidemiological, Clinical, Therapeutic and Evolutive Aspects of Graves’s Disease in the Department of Internal Medicine at CHU Aristide Le Dantec, Dakar (Senegal). Pan African Medical Journal, 25, 6. https://doi.org/10.11604/pamj.2016.25.6.7868
[15]
Boiro, D., Diédhiou, D., Niang, B., et al. (2017) Hyperthyroidism in Children at the University Hospital in Dakar (Senegal). Pan African Medical Journal, 28, 10. https://doi.org/10.11604/pamj.2017.28.10.13396
[16]
Léger, J. and Carel, J.C. (2013) Hyperthyroidism in Childhood: Causes, When and How to Treat. Journal of Clinical Research in Pediatric Endocrinology, 5, 50-56.
[17]
Deleveaux, I., Chamoux, A. and AumaÎtre, O. (2013) Stress and Auto-Immunity. La Revue de Médecine Interne, 34, 487-492. https://doi.org/10.1016/j.revmed.2012.10.366
[18]
Manji, N., Carr-Smith, J.D., Boelaert, K., et al. (2006) Influences of Age, Gender, Smoking, and Family History on Autoimmune Thyroid Disease Phenotype. The Journal of Clinical Endocrinology & Metabolism, 91, 4873-4880. https://doi.org/10.1210/jc.2006-1402
[19]
Hadj Ali, I., Khiari, K., Chérif, L., et al. (2004) Treatment of Graves’ Disease: 300 Cases. La Presse Médicale, 33, 17-21. https://doi.org/10.1016/S0755-4982(04)98466-7
[20]
Magri, F., Zerbini, F., Gaiti, M., et al. (2016) Gender Influences the Clinical Presentation and Long-Term Outcome of Graves Disease. Endocrine Practice, 22, 1336-1342. https://doi.org/10.4158/EP161350.OR
[21]
Leger, J., Kaguelidou, F., Alberti, C. and Carel, J.C. (2014) Graves’ Disease in Children. Best Practice & Research Clinical Endocrinology & Metabolism, 28, 233-243. https://doi.org/10.1016/j.beem.2013.08.008
[22]
Akossou, S.Y., Napporn, A., Oeh-Akuee, G., et al. (2001) Problems in the Management of Thyrotoxicosis in Black Africa: The Tongolese Experience. Annales d’Endocrinologie, 62, 516-520.
[23]
Wong, K.P. and Lang, B.H. (2011) Graves’ Ophthalmopathy as an Indication Increased the Risk of Hypoparathyroidism after Bilateral Thyroidectomy. World Journal of Surgery, 35, 2212-2218. https://doi.org/10.1007/s00268-011-1236-y
[24]
Diédhiou, D., Sow, D., Lèye, M.M., et al. (2017) Cardiothyreosis: Risk Factors and Clinical Profile. Open Journal of Internal Medicine, 7, 1-11. https://doi.org/10.4236/ojim.2017.71001
[25]
Bouziane, T., Larwanou, M. and El Ouahabi, H. (2017) The Predictive Factors of Relapse in Graves Disease Treated by ATS: About 72 Cases. Annales d’Endocrinologie, 78, 326-352. https://doi.org/10.1016/j.ando.2017.07.370
[26]
Kahalya, G.J., Bartalenab, L., Hegedüsc, L., Leenhardtd, L., Poppee, K. and Pearcef, S.H. (2018) 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. European Thyroid Journal, 7, 167-186. https://doi.org/10.1159/000490384
[27]
Klein, I., Becker, D.V. and Levey, G.S. (1994) Treatment of Hyperthyroid Disease. Annals of Internal Medicine, 121, 281-288. https://doi.org/10.7326/0003-4819-121-4-199408150-00010
[28]
Sundaresh, V., Brito, J.P., Wang, Z., et al. (2013) Comparative Effectiveness of Therapies for Graves’ Hyperthyroidism: A Systematic Review and Network Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism, 98, 3671-3677. https://doi.org/10.1210/jc.2013-1954
[29]
Struja, T., Fehlberg, H., Kutz, A., et al. (2017) Can We Predict Relapse in Graves’ Disease? Results from a Systematic Review and Meta-Analysis. European Journal of Endocrinology, 176, 87-97. https://doi.org/10.1530/EJE-16-0725
[30]
Léger, J. and Carel, J.C. (2017) Magement of Endocrine Disease/Arguments for the Prolonged Use of Antithyroid Drugs in Children with Graves’ Disease. European Journal of Endocrinology, 177, 59-67. https://doi.org/10.1530/EJE-16-0938
[31]
Kaguelidou, F., Alberti, C., Castanet, M., Guitteny, M.A., Czernichow, P. and Leger, J. (2008) Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment. The Journal of Clinical Endocrinology & Metabolism, 93, 3817-3826. https://doi.org/10.1210/jc.2008-0842
[32]
Vos, X.G., Endert, E., Zwinderman, A.H., Tijssen, J.G. and Wiersinga, W.M. (2016) Predicting the Risk of Recurrence before the Start of Antithyroid Drug Therapy in Patients with Graves’ Hyperthyroidism. The Journal of Clinical Endocrinology & Metabolism, 101, 1381-1389. https://doi.org/10.1210/jc.2015-3644
